News

PwC's 2026 Mid-Year M&A Outlook Names India as the Emerging Market That Global Health Industries Dealmakers Cannot Ignore Anymore

By Darshan S, Editor · 03 July,2026 · 2 min read

Summary

• PwC 2026 Mid-Year M&A Outlook: India Named as Emerging Global Health Industries Dealmaker With Three Convergent Themes
• PwC's Global Health Industries M&A Mid-Year Outlook 2026 identifies India as increasingly relevant to global dealmakers, combining consumer demand, manufacturing capability, and technology-enabled care — with Sun Pharma's Organon deal as the landmark outbound acquisition example.

"India is becoming increasingly relevant to global health industries M&A as fast-growing consumer demand, expanding clinical and manufacturing capability, and technology-enabled care models converge. India increasingly brings together three important themes: consumer demand, scalable capability, and technology-enabled care. We expect it to feature more often in cross-border activity through the second half of 2026 and beyond, both as an investment destination and as an emerging outbound acquirer."

PwC's Global Health Industries M&A Mid-Year Outlook for 2026, published this week, provides what is likely the most prominent positioning of India's healthcare sector within a major global investment banking and advisory firm's strategic analysis in recent years. The report identifies India as an increasingly relevant participant in global health industries deal activity — not merely as a manufacturing partner or investment destination for private equity seeking growth market exposure, but as an emerging outbound acquirer whose larger pharmaceutical companies are conducting cross-border transactions at a scale and sophistication that requires global dealmakers to understand India as a strategic actor, not just a market.

The PwC analysis identifies three convergent themes that make India increasingly important to global health industries dealmakers. The first is consumer demand: a growing middle class with increasing willingness to pay for quality healthcare, a large and expanding government health insurance base through Ayushman Bharat (42 crore-plus cardholders), greater consumer willingness to pay privately for specialist and preventive healthcare, and rapid digital adoption creating new channels for health service delivery. The second is scalable capability: India's pharmaceutical manufacturing infrastructure, expanding CDMO capacity, clinical trial network, and medical technology manufacturing ecosystem create cost-efficient, high-quality production capability that global companies are actively seeking. The third is technology-enabled care: India's preventive health platforms, AI diagnostics deployments, and digital health infrastructure present models that could become relevant beyond India as other markets seek lower-cost, digitally enabled ways to meet rising healthcare demand.

India as Outbound Acquirer — The Sun Pharma-Organon Example

PwC's report directly cites Sun Pharma's acquisition of US-based Organon as the landmark example of the new Indian outbound acquirer model. The analysis notes that the acquisition brings scale in women's health, established brands, and biosimilars to an Indian buyer at a size and complexity not previously seen from the Asia-Pacific region — and that it shows how larger Indian pharma companies are looking beyond their home market to add capabilities, brands, and global reach.

This framing is significant coming from PwC — a firm whose global health industries M&A practice advises on some of the largest transactions in the sector. Including Sun Pharma-Organon alongside Eli Lilly-Centessa, Merck KGaA-Bio-Techne, and Danaher-Masimo as illustrative transactions in the mid-year outlook places India's outbound acquisitions in the same strategic tier as Western megadeals — recognising Indian pharmaceutical companies as global strategic actors rather than regional players.

The Private Equity and Consolidation Opportunity

Within India, PwC identifies the private equity-driven consolidation opportunity as significant: a large middle class, government health insurance, greater willingness to pay privately, and rapid digital adoption are creating opportunities across consumer health, hospitals, specialist clinics, and digital health for private equity to accelerate consolidation within India's highly fragmented domestic healthcare sector.

This framing aligns precisely with the deal patterns BHC Media has tracked throughout 2026: ChrysCapital's $157 million acquisition of 71% in Novartis India, the Apollo-Cloudnine ₹1,550 crore maternity-fertility merger, Max Healthcare's Kalinga Bhubaneswar acquisition, and the HealthQuad Fund III Rs 550 crore close (covered in yesterday's edition). Each represents a different dimension of the private equity consolidation wave that PwC's global analysis is describing.

H2 2026 Expectations

PwC's mid-year report projects continued M&A momentum through the second half of 2026 — with oncology, metabolic disease, vaccines, and radiopharma as the key therapeutic area M&A targets globally, and India featuring more often in cross-border activity both as an investment destination and as an emerging outbound acquirer. The India-specific pipeline for H2 2026 includes: Manipal Hospitals IPO (SEBI approval pending, covered in BHC Media's June 1 edition), Sun Pharma's Organon deal close (expected December 2026), and the continued BIOSECURE Act implementation creating a sustained qualification wave toward Indian CDMOs.

"BHC Perspective"

At Bengaluru Health Community, PwC's recognition of India's three convergent healthcare M&A themes — consumer demand, scalable capability, and technology-enabled care — is the global institutional validation of what BHC has been building its ecosystem around since launch. Every BHC mentorship session connecting a healthcare founder with a regulatory, clinical, or commercial expert is an investment in the scalable capability dimension. Every HMEP cohort producing healthcare managers is an investment in the consumer demand dimension. Every BHC Media edition documenting India's digital health and AI adoption is documenting the technology-enabled care dimension. The global healthcare M&A community is now paying attention to the same story BHC has been telling.

Frequently Asked Questions

Q: What does PwC say about India in its 2026 M&A outlook?
A: PwC identifies India as increasingly relevant to global health M&A, converging three themes: consumer demand (middle class, Ayushman Bharat, digital adoption), scalable capability (pharma manufacturing, CDMOs, clinical trials), and technology-enabled care (preventive health, AI diagnostics, digital health at scale).

Q: What Indian deal does PwC cite?
A: Sun Pharma's acquisition of US-based Organon — noted as the landmark example of a new Indian outbound acquirer model, bringing scale in women's health, brands, and biosimilars to an Indian buyer at a size and complexity not previously seen from Asia-Pacific.

Q: What does PwC expect for H2 2026?
A: India to feature more often in cross-border health M&A activity, both as investment destination and emerging outbound acquirer. Global M&A focused on oncology, metabolic disease, vaccines, and radiopharma. India-specific pipeline includes Manipal Hospitals IPO, Sun Pharma-Organon close, and BIOSECURE Act-driven CDMO qualification wave.